Home › Employers › Leap Therapeutics Inc.
Leap Therapeutics Inc.: H-1B salaries and sponsorship
Leap Therapeutics Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $210,000.
Does Leap Therapeutics Inc. sponsor H-1B visas?
Leap Therapeutics Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on May 28, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Associate Director, PV Operations | 1 | $185,000 |
| Director, Biostatistics | 1 | $210,000 |
| Director, Downstream Process Development and Manufacturing | 1 | $210,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $197,500 |
| FY2024 | 1 | $210,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Director, Downstream Process Development and Manufacturing | $210,000 Level IV | Cambridge, MA | May 28, 2024 | Oct 1, 2024 | Certified |
| Director, Biostatistics | $210,000 Level IV | Lansdale, PA | Apr 14, 2023 | May 1, 2023 | Certified |
| Associate Director, PV Operations | $185,000 Level IV | Monrovia, MD | Oct 11, 2022 | Oct 24, 2022 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).